Mechanics Cooperative Bank is proud to be a local community bank, focused on support-ing the banking needs of local families and local small businesses. We have products and services that can match any financial institution and offer a more in-depth understanding of the local business market. Were responsive to your unique busi-ness needs and can react quickly to growth opportunities. Our philosophy is simple when it comes to serving our business customers – when your business succeeds, we succeed. Mechanics Cooperative Bank currently operates 9 branch locations throughout Taunton, North Dighton, Bridgewater, Fall River, Westport, Swansea, Somerset and New Bedford. Member FDIC. Member DIF. Equal Housing Lender. NMLS #421820
XLI is a full service manufacturer of precision engineered mechanical components and complex electro-mechanical subassemblies for applications including motorized vehicles, firearms, security instrumentation and communications. XLI manufactures your product according to your specifications and delivery requirements on a repetitive, low volume production basis in our U. S. facilities. Our organization provides complete customer support from engineering to manufacturing to product testing, packaging and delivery to streamline your procurement effort and expense.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Our proprietary software and professional team of CPAs have assisted thousands of businesses retain hundreds of millions of dollars in stimulus funding